

1 Microbiome compositions and fecal metabolite concentrations predict post-operative infection in liver
2 transplant recipients

3 Christopher J Lehmann¹, Nicholas P Dylla², Matthew Odenwald³, Ravi Nayak², Maryam Khalid², Jaye Boissiere²,
4 Jackelyn Cantoral², Emerald Adler², Matthew R Stutz⁴, Mark Dela Cruz⁵, Angelica Moran⁶, Huaiying Lin¹, Anitha
5 Sundararajan¹, Ashley M. Sidebottom¹, Eric G Pamer^{1,2}, Andrew Aronsohn³, John Fung⁷, Talia B Baker⁸, Aalok
6 Kacha⁹

7

8 Christopher J Lehmann, MD¹

9 5841 South Maryland Ave., MC 5065

10 Chicago, IL 60637

11 Christopher.lehmann@bsd.uchicago.edu

12 +1-773-702-7632

13 Eric G Pamer^{1,2}

14 egpamer@bsd.uchicago.edu

15 Aalok Kacha⁹

16 akacha@bsd.uchicago.edu

17 ¹Department of Medicine, Section of Infectious Disease and Global Health, University of Chicago Medicine, 5841
18 South Maryland Ave, Chicago, IL, 60637, USA

19 ²Duchossois Family Institute, Biological Sciences Division, University of Chicago, 900 E. 57th St, Chicago, IL 60637,
20 USA

21 ³Department of Medicine, Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago
22 Medicine, 5841 South Maryland Ave, Chicago, IL, 60637, USA

23 ⁴Department of Pulmonary and Critical Care Medicine, Cook County Health, 1950 W. Polk St, Chicago, IL 60612,
24 USA

25 ⁵Department of Cardiology, Advocate Health Care Systems, 4400 W. 95th St, Oak Lawn, IL, 60453, USA

26 ⁶Department of Pathology, University of Chicago Medicine, 5841 South Maryland Ave, Chicago, IL, 60637, USA

27 ⁷Department of Surgery, Section of Transplant Surgery, University of Chicago Medicine, 5841 South Maryland
28 Ave, Chicago, IL, 60637, USA

29 ⁸Department of Surgery, Division of Transplantation and Advanced Hepatobiliary Surgery, University of Utah
30 Health, 30 N. 1900, East Salt Lake City, UT, 84132, USA

31 ⁹Department of Anesthesia and Critical Care, University of Chicago Medicine, 5841 South Maryland Ave,
32 Chicago, IL, 60637, USA

33 **ABSTRACT:**

34 **Background:** Liver transplantation (LT) is associated with postoperative infections caused by antibiotic-resistant
35 bacterial pathogens that reside in the intestine. An intact intestinal microbiome suppresses expansion of enteric
36 pathogens, however patients with severe liver disease often have reduced microbiome diversity and increased
37 density of antibiotic-resistant *Enterococcus* and *Enterobacterales* species. (1–4) Experimental models have
38 demonstrated that metabolites produced by the intestinal microbiome, including short chain fatty acids (SCFAs),
39 secondary bile acids and indole compounds, enhance host epithelial and immune defenses against enteric
40 pathogens.(5–10) Microbiome derived metabolites likely contribute to resistance against infectious diseases in
41 LT patients, however, this remains uninvestigated.

42 **Methods:** We prospectively enrolled 107 liver transplant candidates and determined peri-transplant fecal
43 microbiome compositions including relative and absolute fecal metabolite concentrations.

44 **Results:** Fecal microbiomes in LT recipients ranged from highly diverse to complete loss of diversity resulting in
45 expansion of *Enterococcus* and/or *Enterobacterales* species that were associated with postoperative infection.
46 Gas chromatographic (GC-) and liquid chromatographic (LC-) Mass spectrometric analyses revealed decreased
47 concentrations of SCFAs, secondary bile acids, and indole compounds in fecal samples with low microbiome
48 diversity and associated expansion of *Enterococcus* and *Enterobacterales* populations.

49 **Conclusion:** Fecal metabolite abundances accurately predicted LT patients with reduced microbial diversity and
50 those who developed postoperative infection.

51

52 **KEY WORDS:**

53 Microbiome; Metabolome; Liver Transplant; Enterococcus; Enterobacterales

54 **RUNNING TITLE:**

55 Microbiome of Postoperative Infection

56

57 **INTRODUCTION:**

58 Liver transplantation (LT) is the definitive treatment for end-stage liver disease. Despite advances in antibiotic
59 prophylaxis, patient selection, donor screening, organ preservation, and surgical technique, infection remains a
60 leading cause of morbidity and mortality. (11–13) *Enterococcus* species and members of the order
61 *Enterobacterales*, such as *Escherichia coli* and *Klebsiella pneumoniae*, remain among the most common causes of
62 infection in the post-transplant period. The clinical impact of these infections is compounded by rising rates of
63 antibiotic resistance, with vancomycin resistant *Enterococcus faecium* (VRE) and multiple drug resistant
64 *Enterobacterales* making outsized contributions to morbidity and mortality. (12, 13)

65 *Enterococcus* and *Enterobacterales* species are normal inhabitants of the human gut microbiota. (14, 15) In
66 healthy individuals, these facultative anaerobes compose a small fraction of the microbiota but are capable of
67 markedly expanding following loss of microbiota diversity. (16, 17) Pathogen expansion in the gut increases the
68 risk of systemic infection in a variety of disease states. (18, 19) How the microbiome suppresses *Enterococcus*
69 and *Enterobacterales* expansion in the gut and prevents systemic infections is an active area of investigation
70 with increasing evidence supporting the role of microbiota-derived metabolites, especially SCFAs, secondary bile
71 acids, and indole compounds in bacterial growth inhibition and enhancement of host immune and epithelial
72 barrier defenses. (20–24)

73 The intestinal microbiota is impacted by liver disease and gut microbial populations produce metabolites and
74 other products that circulate via the portal vein and impact liver function. (25–27) A prospective study of LT
75 patients demonstrated that the majority were colonized with multidrug-resistant organisms (MDROs), which
76 was associated with increased rates of MDRO infections. (1) A follow-up study demonstrated that colonization
77 with MDROs was associated with reduced microbiota diversity, as determined by 16S rRNA gene sequencing. (2)
78 How microbiota-derived metabolites contribute to colonization resistance against MDROs and whether
79 metabolite profiling can identify patients at high risk for MDRO infections remains open questions.

80 To determine the dynamic between the microbiota, microbiota-derived metabolites, MDRO expansion in the gut
81 and invasive infection in liver transplant recipients, we performed a prospective surveillance study assessing
82 fecal microbial composition and microbe-derived metabolite concentrations. We demonstrate that expansion of
83 MDRO populations in the fecal microbiota correlates with increased risks of infection and that patients with low
84 concentrations fecal SCFA, secondary bile acids and a subset of indole compounds are more likely to have
85 *Enterococcus* expansion. Further, specific microbiome derived metabolite profiles identify patients with lost

86 diversity as well as postoperative bacterial infection. Metabolomic profiling provides many advantages over
87 metagenomic methods which are much slower and more expensive.

88 **RESULTS:**

89 *Microbiome compositions in liver transplant patients is widely variable*

90 We conducted a prospective fecal microbiome and metabolome study on patients admitted to the University of
91 Chicago Medical center for liver transplantation and enrolled 158 patients, of whom 28 did not undergo
92 transplantation and 23 did not provide a fecal sample from 7 days prior to 30 days after transplantation
93 (Supplementary Figure 1). For the 107 patients who underwent LT and from whom fecal samples were
94 collected, the causes of end-stage liver disease were varied and included alcoholic cirrhosis/hepatitis (56%),
95 malignancy (21%), non-alcoholic fatty liver disease (15%), and others (Table 1).

96 We determined fecal microbiota compositions in LT recipients by shotgun metagenomic sequencing in the peri-
97 transplant period and implemented MetaPhlan-4 for determining the relative composition of microbial
98 communities. (28) Microbiome composition and diversity varied widely between the 107 patients, with some
99 approximating healthy donors (HD) and others being dominated by single bacterial taxa (Figure 1). To
100 determine whether microbiome compositions influence post-transplant outcomes, we divided LT patients into
101 three groups on the basis of microbiota diversity, with 27 high diversity patients falling within the range of
102 diversities detected in the HD group and the remaining 80 LT patients were evenly divided into low and medium
103 diversity groups. A taxUMAP of the 107 LT patients and 21 healthy donors revealed close clustering between
104 the subset of high diversity LT and HD fecal samples while most of LT patient samples harbored microbiota with
105 distinct and wide-ranging compositions (Figure 1). While high diversity LT patient and HD microbiome
106 compositions shared some similarities, LT patients had significantly lower relative abundance of *Oscillospiraceae*
107 (synonym *Ruminococcaceae*) ($W(48) = 117, p < 0.001$, two-tailed test), and higher abundance of
108 *Enterobacterales* ($W(48) = 487, p < 0.001$, two-tailed). In contrast, low and medium diversity LT patients differed
109 from high diversity patients in nearly every measured metric. In addition to reduced diversity, the low and
110 medium diversity groups had lower abundances of the phylum Bacteroidetes ($W(64) = 57, p < 0.001$, two-tailed;
111 $W(67) = 342, p = 0.014$, two-tailed, respectively) and families *Lachnospiraceae* ($W(64) = 0, p < 0.001$, two-tailed;
112 $W(67) = 140, p < 0.001$, two-tailed, respectively) and *Oscillospiraceae* ($W(64) = 32, p < 0.001$, two-tailed;
113 $W(67) = 190, p < 0.001$, two-tailed, respectively). Increases in *Enterococcus* and *Enterobacterales* ($p < 0.001$)
114 abundance were common in low and medium diversity LT patients. Many increases amounted to >90% of the
115 entire composition of the microbiome, with 40% of LT patients having greater than 20% *Enterococcus* relative

116 abundance and 17% of patients having greater than 5% *Enterobacterales* relative abundance. To ensure stool
117 samples corresponded to the perioperative period, a histogram of stool sample collections was created
118 (Supplemental Figure 2). The median day to stool collection was post-operative day 4, with most samples being
119 collected within the first 7 days before or after transplant. There was no difference in stool collection timing
120 between diversity groups.

121 Although reduced abundance of beneficial taxa and expansion of *Enterococcus* and *Enterobacterales* species are
122 known to occur in chronic liver disease and LT patients, the consequences of these compositional shifts on the
123 microbiota-derived metabolome remain undefined. (1–4) We performed targeted GC- and LC-MS analyses for
124 metabolites produced or modified by the gut microbiota on peri-transplant fecal samples from the LT patient
125 cohort (Figure 2). Within the LT patient cohorts, relative amounts of butyrate, valerate, and hexanoate varied
126 dramatically, with patients in the low and medium diversity cohorts having markedly reduced levels while those
127 in the high diversity group approached the range seen in the healthy donors.

128 We detected markedly reduced concentrations of secondary bile acids and corresponding increases in
129 concentrations of conjugated and primary bile acids among low and medium diversity LT patients, indicating loss
130 of microbial bile acid deconjugating and 7 α -dehydroxylation capacity. (29, 30) Fecal samples from LT recipients
131 had increased abundance of amino acids, however this increase did not correlate with microbiota diversity or
132 composition and thus may be a consequence of chronic liver disease and/or recent liver transplantation.
133 Microbiota derived vitamins biotin, pantothenic acid, niacin, and folate were reduced in low diversity LT
134 patients, likely reflecting loss of gut commensal bacteria that produce B vitamins, in particular species belonging
135 to the phylum Bacteroidetes. (31) *P*-Cresol, a microbiome derived phenol which has been linked to
136 cardiovascular risk in chronic kidney disease was also reduced in low diversity LT patients. (32) Only one
137 microbiome derived metabolite, tyramine, which is produced by *Enterococcus faecalis* and *Enterococcus*
138 *faecium*, is significantly more abundant in liver transplant recipients. (33)

139 Mass spectrometric quantitation of acetate, propionate and butyrate concentrations in fecal samples from LT
140 patients revealed marked reductions in patients with low microbiota diversity [Figure 3] while the high diversity
141 LT patients had SCFA concentrations in the same range as fecal samples from healthy subjects. Conjugated and
142 unconjugated primary bile acids were present at very low concentrations in fecal samples from healthy subjects
143 and high diversity LT patients while several low and medium diversity fecal samples had much higher
144 concentrations. In contrast, fecal secondary bile acid concentrations were markedly lower in low and medium
145 diversity compared to high diversity samples. Quantitation of fecal metabolites reveals the remarkable range of
146 metabolic activity in the lower intestinal tract microbiota of LT patients, a the subset of patients with near

147 normal microbiota diversity having metabolite concentrations within the normal range while the majority of LT
148 patients, in particular those with the lowest microbiota diversities, have markedly reduced and in many cases
149 absolute absence of beneficial metabolites.

150 To determine whether taxonomic changes in microbiome composition or changes in microbial metabolism
151 impact the risk for postoperative infection, we evaluated LT patients for infections in the first 30 days following
152 transplant. Of the 107 LT recipients, 25 developed bacterial infection. [Supplemental Figure 1] We compared the
153 taxonomic composition of stool samples collected closest to the time of infection and compared them to peri-
154 transplant samples from patients who did not develop infection. There were no significant differences in the
155 age, sex, or race between patients with or without infection. [Table 1] Additionally, there were no differences in
156 indication for transplant, Model of End Stage Liver Disease-Na (MELD-Na) score, use of mechanical ventilation,
157 renal replacement therapy, vasopressors, immunosuppression, or antibiotic administration between the groups.
158 The most common site of infection was intra-abdominal (50%), followed by urinary tract (20%), and skin (13%).
159 [Supplemental Table 1] The most common organisms causing infection were members of the genus
160 *Enterococcus* (45%) and order *Enterobacterales* (20%). No specific organism was identified in 5 (13%) infections.

161 Table 1

162 *Expansion of Enterococcus and Enterobacterales is associated with postoperative infection*

163 Because *Enterococcus* and *Enterobacterales* were the most common causes of infection, we determined
164 whether increases of these taxa was associated with the risk of invasive infection. Perioperative fecal samples
165 were ordered by relative abundance of *Enterococcus* or *Enterobacterales* and compared to causes of infection.
166 [Figure 4]. Infections caused by *Enterococcus* clustered with fecal samples with increased densities of
167 *Enterococcus*, while *Enterobacterales* infections occurred in patients with increased fecal *Enterobacterales*
168 density (Figure 4). However, many patients with expansion of pathobiont species did not develop invasive
169 infections, suggesting that other unidentified factors, such as immune and mucosal barrier defenses and other
170 clinical factors likely also contribute to the risk of infection.

171 Receiver operator characteristic (ROC) analyses were performed to determine correlations between intestinal
172 expansion of pathobionts with infection and optimized for sensitivity and specificity. The optimized threshold
173 determined for *Enterococcus* relative abundances predicting *Enterococcus* infections was 19.9%. At this
174 threshold expansion of *Enterococcus* predicts infection with sensitivity of 88% ([CI]: 65%-100%), specificity of
175 70% ([CI]: 59%-94%) and an area under the curve of 0.83 ([CI]: 0.74-0.91) (Figure 4). Expansion of *Enterococcus*
176 >19.9% occurred in 41% of LT patients and accounts for 15 of the 17 (88%) of *Enterococcus* infections

177 (Supplemental Table 2). For *Enterobacterales*, a threshold of 2.5%, relative abundance predicted infection with
178 sensitivity of 100% ([CI]: 100%-100%), specificity of 80% ([CI]: 72%-94%) and an area under the curve of 0.91
179 ([CI]: 0.82-0.96) (Figure 4). *Enterobacterales* expansion at or above 2.5% occurred in 27% of LT patients and
180 accounted for all 8 (100%) *Enterobacterales* infections.

181 Figure 4

182 *Microbiome derived metabolites associated with Enterococcus expansion*

183 To determine whether fecal metabolite concentrations identify patients with *Enterococcus* or *Enterobacterales*
184 expansion, we generated volcano plots comparing log₂ fold changes of metabolites (relative to the median value
185 of each compound) against statistical significance, with p-values adjusted for multiple comparisons following the
186 Benjamini-Hochberg method (Figure 5). Expansion was defined as >=19.9% for *Enterococcus* and 2.5% for
187 *Enterobacterales*, as determined in Figure 4. A variety of metabolites were enriched in samples without
188 *Enterococcus* expansion and included several secondary bile acids: lithocholic, isolithocholic, allolithocholic,
189 isodeoxycholic, alloisolithocholic, 3-oxolithocholic, and 12-oxolithocholic acids. Butyrate, valerate, propionate,
190 and hexanoate were also enriched in patients without *Enterococcus* expansion. Other microbially derived
191 metabolites that were enriched in patients without expansion included the tryptophan-derived metabolite
192 indole-3-propionate, the vitamin biotin, and a number of branched chain fatty acids. Fifteen metabolites were
193 enriched in patients with *Enterococcus* expansion, including multiple conjugated bile acids, likely indicating
194 reduced microbiome-mediated bile acid deconjugation. Tyramine, a tyrosine derived amine produced by *E.*
195 *faecium* and *E. faecalis* and several amino acids were also enriched in expanded samples. To confirm the trends
196 established by qualitative analysis, a subset of metabolites with previously established beneficial effects were
197 measured quantitatively against standardized controls. Of these, many of the same SCFA and secondary bile
198 acids were enriched in samples without expansion. (Figure 5) The primary bile acid cholic acid and conjugated
199 bile acid taurocholic acid were enriched in samples with expansion. The smaller number of LT patients with fecal
200 *Enterobacterales* expansion precluded identification of statistically significant metabolite associations after
201 correcting for multiple comparisons (data not shown).

202 While microbiota composition and diversity correlate with fecal metabolomic profiles (Fig. 2), the ability of
203 metabolomic profiling to predict microbiota compositions remains largely untested. Given the speed of
204 metabolomic profiling compared to metagenomic sequence analysis and the interest in real-time identification
205 of patients for potential microbiota reconstitution therapies, we decided to determine how accurately fecal
206 metabolite concentrations predict microbiota diversity and the risk of infection. Using 93 metabolite

207 measurements per fecal sample, sparse partial least squares discriminant analysis (sPLS-DA) (34) predicted low,
208 medium, and high diversity groups with high sensitivity, specificity, and accuracy (Figure 6A) 70% ([CI]: 59.7%-
209 78.3%). Secondary bile acids, short- and branched-chain fatty acids correlated most significantly with high
210 diversity microbiota (Supplementary Figure 3). While the model most accurately identified low diversity fecal
211 samples, only misidentifying 1 of 37 as high diversity, 7 of 26 high diversity samples were identified as low
212 diversity, suggesting that exogenous factors such as diet may influence the metabolic activity of resident
213 commensal bacteria.

214 Fecal metabolite levels also accurately predict pathobiont dissemination beyond the gut to sites of
215 postoperative infection such as the peritoneal cavity, urinary tract, or bloodstream (Figure 6B). Samples
216 obtained from patients with infection clustered distinctly from those without infection, with an overall accuracy
217 of 82% ([CI]: 73.9%-89.1%), a strong odds ratio (13.6 ([CI]: 4.8-38.6) and high specificity of 89% ([CI]: 80%-94.8%).
218 Sensitivity for infection was slightly lower 63% ([CI]: 42.4%-80.6%), likely reflecting multifactorial causality of
219 infection following LT. To determine which metabolites made the greatest contribution to the PLS-DA models,
220 metabolite loadings for each axis were assembled in separate plots (Supplemental Figure 4). The largest
221 contributors to the model's first two components were tyramine, conjugated bile acids, indole derivatives, and
222 SCFAs in patients who remained uninfected.

223 **DISCUSSION:**

224 Every LT patient follows a distinct path from health to end-stage liver disease (ESLD). Some patients develop
225 acute, fulminant hepatitis over the course of days, while others progressively lose hepatic function over many
226 years due to chronic, progressive fibrosis leading to cirrhosis and end stage complications. The wide range of
227 microbiome compositions we and others have detected in LT cohorts (1–4) likely result from diversity of
228 diseases leading to ESLD, differing treatments modalities, including exposure to antibiotics for infections such as
229 spontaneous bacterial peritonitis and acquisition of antibiotic-resistant pathobionts. We demonstrate that
230 targeted mass spectrometric analysis of fecal samples identify LT patients with partial to complete loss of
231 metabolites that impact pathobiont fitness, host immune defenses, and mucosal barrier integrity. Loss of
232 beneficial metabolites closely correlates with loss of bacterial taxa that constitute a diverse microbiota and
233 identifies patients with an increased risk of postoperative infections caused by antibiotic-resistant pathobionts.

234 The ability of the intestinal microbiota to protect against enteric infection has been appreciated for over 70
235 years, with Bohnhoff et al. and Freter et al. (35, 36) demonstrating that antibiotic treatment alters the intestinal
236 microbiota and renders mice markedly more susceptible to infection by enteric pathogens. Subsequent

237 experimental studies demonstrated that SCFA and secondary bile acid production by obligate anaerobic
238 commensal bacterial species suppress enteric pathogens and pathobionts. (22–24, 36) Microbiota also enhance
239 immune defenses in the gut through induction of IL-23 secretion by lamina propria dendritic cells, which drives
240 IL-22 production by innate lymphocytes which in turn stimulates growth of epithelial stem cells and production
241 of antibacterial C-type lectins such as RegIII γ . (37) These lectins inhibit many human pathogens, including
242 *Enterococcus faecium*, *Escherichia coli*, and other enteric gram negatives. In parallel, production of indole
243 compounds by microbiota-mediated tryptophan metabolism drives differentiation of immune cells by triggering
244 the aryl-hydrocarbon receptor (AHR) and enhancing IL-22 production. (38) Our findings support the notion that
245 a diverse microbiome, with the capacity to produce SCFAs, secondary bile acids and AHR ligands, enhances
246 resistance of LT patients to pathobiont expansion in the gut lumen and invasive infection from the gut.

247 The contributions of commensal bacterial species and their metabolic products to disease resistance in clinical
248 settings are challenging to disentangle. Treatment with broad-spectrum antibiotics, the most common cause of
249 microbiome compromise, was very common in our cohort, which results in concurrent depletion of many
250 microbial taxa and microbiota-derived metabolites. (16, 39, 40) Loss of beneficial Bacteroidetes,
251 *Lachnospiraceae* and *Oscillospiraceae* are paralleled by loss of SCFAs, secondary bile acids and indole
252 compounds, making it impossible to pinpoint a specific deficiency that renders patients more susceptible to
253 infection. It is likely that disease resistance is not fully attributable to any one component but instead results
254 from the aggregate contributions of different components. While the specific mechanisms by which a diverse
255 microbiota and resulting metabolites mediate protection from infection remain to be defined, the correlative
256 results obtained from non-interventional studies suggest that clinical trials of therapeutic interventions to re-
257 establish missing commensal bacterial populations and normalize metabolite profiles are warranted.

258 Metagenomic analyses of fecal samples require deep nucleic sequencing platforms and bioinformatic analyses
259 that continue to evolve as bacterial genome databases grow, microbial nomenclature changes, and microbial
260 gene annotation improves. Targeted metabolomic analyses by mass spectrometry, on the other hand, are rapid,
261 accurate, and bioinformatic platforms to define features and provide chemical structures are well established.
262 Our findings demonstrate that patients with compromised microbiomes, as defined by metagenomic analyses,
263 can be identified by measuring fecal SCFAs, bile acids, and a narrow range of microbially generated metabolites.
264 Not only can patients with reduced diversity be identified, but also those at increased risk for invasive bacterial
265 infection. Given the rapidity with which microbiome compositions can change from one day to another, (41)
266 obtaining same-day results would provide critical, real-time insights to guide clinical interventions to improve

267 microbiome compositions and functions, such as therapy with live biotherapeutic products and/or microbiome
268 modulating foods.

269 Our study has several limitations. Most importantly, while we demonstrate that the incidence of infection is
270 associated with fecal microbiome compositions and metabolite concentrations, we are unable to prove
271 causation. Future studies that intervene on microbiome and/or metabolite deficiencies are required to
272 determine whether the reintroduction of specific bacterial taxa and/or their metabolic products reduces
273 infection and resultant morbidity, mortality, and healthcare utilization. Our study is limited to one institution
274 and, in contrast to other studies of microbiome compositions in LT patients, has a higher proportion of patients
275 with ethanol associated liver disease and a low proportion of patients with hepatitis C related liver disease.
276 While this makes our study distinct from prior studies, it closely represents cohort of contemporary patients
277 who are being treated with transplantation. (42) The care of postoperative LT patients is very protocolized and
278 center specific. Perioperative antibiotic use, nutrition, indications for transplant, hospital antibiogram, infection
279 control practices, and many other factors are likely specific to our institution and may have influenced our
280 findings. Thus, our findings may not directly extend to substantially different patient populations.

281 In conclusion, our study demonstrates that targeted fecal metabolite measurements can identify a large subset
282 of patients undergoing LT with markedly deficient microbiome compositions. The ability to rapidly identify
283 patients with an increased risk of postoperative infection should facilitate the development of strategies that
284 preserve or reconstitute microbiome functions and lead to approaches that prevent exposure to antibiotic-
285 resistant pathobionts. As administration of well-characterized microbes to reconstitute the microbiome evolves,
286 rapid fecal metabolite monitoring will facilitate the development of personalized microbial consortia that
287 correct metabolite deficiencies.

288 **METHODS:**

289 *Patient Enrollment:*

290 Patients eligible for LT or having recently undergone LT at University of Chicago Medicine were recruited to the
291 protocol (IRB20-0163. Healthy subjects were recruited from the University of Chicago campus and were
292 screened for absence of recent antibiotic treatment and autoimmune or other chronic illnesses prior to fecal
293 microbiome and metabolome characterization.

294 *Definition of Postoperative Infection:*

295 All patient records were screened for documentation of clinical infection during the study period. Screening was
296 performed by author CL at 1-month intervals. Infection was defined as any positive test for infection
297 (microbiological, molecular, biochemical, or radiographic) that was documented as a true positive by the
298 treating clinical team in the medical record. The majority of infections were microbiologically defined by culture
299 or polymerase chain reaction. Infections were classified by location, microbiology, and antimicrobial resistance
300 patterns (Supplemental Table 1). Infections were included for comparison if the infection occurred within the
301 first 30 postoperative days and a stool sample was collected within 14 days prior or 2 days following the
302 development of the infection. Each infection was paired with a stool sample collected nearest to the diagnosed
303 infection. In patients who did not develop infection, the stool sample closest to the day of liver transplant was
304 used for comparison.

305 *Inclusion/Exclusion:*

306 Patients were included in this analysis if they received a LT and had a stool sample collected within peri-
307 operative period: days -7 to +30. Patients were excluded from analysis if they developed an infection, but a stool
308 sample was not collected within 14 days preceding or 2 days following the diagnosis of the infection. 158
309 patients were enrolled in the study. 28 patients had not received a LT, 23 patients did not have a stool sample
310 collected within postoperative day -7 to +30, and all patients had a stool sample collected within -14 to +2 days
311 relative to the diagnosis of an infection (Supplemental Figure 1). The remaining 107 patients were included for
312 analysis. 25 patients developed a bacterial infection and 82 did not. 40 unique infections occurred in the cohort
313 because some patients developed more than one infection.

314 *Specimen Collection:*

315 After enrollment, stool samples were collected before and after LT. All stool samples were collected while
316 admitted at University of Chicago Medical Center. Collection was started immediately after study enrollment
317 and continued for up to two years. Each sample was immediately refrigerated and frozen within 24 hours of
318 collection. Microbiota compositions and metabolite profiles were then characterized.

319 *Specimen Analysis:*

320 DNA Extraction: DNA was extracted using the QIAamp PowerFecal Pro DNA kit (Qiagen). Prior to extraction,
321 samples were homogenized by mechanical disruption using a bead beater. Briefly, samples were suspended in a
322 bead tube (supplied by Qiagen) with lysis buffer and homogenized on a bead mill (Fisherbrand). Samples were
323 then centrifuged, and supernatant was resuspended in a reagent that effectively removed inhibitors. DNA was
324 then purified routinely using a spin column filter membrane and quantified using Qubit 2.0 fluorometer.

325 Shotgun Sequencing: Libraries were prepared using 100-200 ng of genomic DNA using the QIAseq FX DNA library
326 kit (Qiagen). Briefly, DNA was fragmented enzymatically into smaller fragments and desired insert size was
327 achieved by adjusting fragmentation conditions. Fragmented DNA was end repaired and 'A's' were added to the
328 3'ends to stage inserts for ligation. During ligation step, Illumina compatible Unique Dual Index (UDI) adapters
329 were added to the inserts and the prepared library was amplified. Libraries were then cleaned up, and library
330 size was measured using a TapeStation (Agilent). Sequencing was performed on the Illumina NextSeq 500
331 platform producing 5-10 million reads. Adapters were trimmed off from the raw reads, and their quality were
332 assessed and controlled using Trimmomatic (v.0.39), (43) then human genome was removed by kneaddata
333 (v0.7.10, <https://github.com/biobakery/kneaddata>). Taxonomy was profiled using metaphlan4 using the
334 resultant high-quality reads. (35) Alpha diversity of fecal samples was calculated using the Inverse Simpson and
335 Shannon indices. Taxonomic uniform manifold approximate projections (taxUMAP) were used to visualize beta
336 diversity (<https://github.com/jsevo/taxumap>).

337 Metabolomic analysis: SCFAs were derivatized with pentafluorobenzyl bromide (PFBBBr) and relatively quantified
338 via negative ion collision induced-gas chromatography-mass spectrometry. Four SCFA's were quantified
339 absolutely: acetate, butyrate, succinate, and propionate ([-]CI-GC-MS, Agilent 8890). (44) Eight bile acids
340 (primary: cholic acid; conjugated primary: glycocholic acid, taurocholic acid; secondary: deoxycholic acid,
341 lithocholic acid, isodeoxycholic acid, alloisolithocholic acid, and 3-oxolithocholic acid) were quantified ($\mu\text{g}/\text{mL}$)
342 by negative mode liquid chromatography-electrospray ionization-quadrupole time-of-flight-MS ([-]LC-ESI-QTOF-
343 MS, Agilent 6546). Eleven indole metabolites were quantified by UPLC-QqQ LC-MS. Seventy additional
344 compounds were relatively quantified using normalized peak areas relative to internal standards.

345 *Statistical Analysis:*

346 All analysis was conducted using R statistical language (v4.2.2 (2022-10-31)) using the RStudio (v2022.12.0+353)
347 integrated development environment. Non-parametric, descriptive statistics, were used to describe the clinical
348 characteristics of patients. All clinical tables were generated using the R package gtsummary. (45) For categorical
349 clinical variables, a Chi-square goodness-of-fit test was implemented. All other continuous variables regressed
350 against categorical variables (e.g. relative abundance vs diversity groups or age vs infection group) were
351 statistically analyzed using a two-tailed, Wilcoxon-rank sum test, from the R package rstatix, (46) unless
352 otherwise noted. All p -values were adjusted to account for multiple comparisons following the Benjamini-
353 Hochberg method. Adjusted p -values of the tests were considered to be statistically significant for all analyses
354 conducted if $p \leq 0.05$. To compare relatively quantified metabolites, \log_2 fold-change ($\log_2\text{FC}$) was calculated
355 per compound using the median value across all fecal samples. These $\log_2\text{FC}$ values were then arranged by

356 statistical significance when comparing the diversity groups (Kruskal-wallis test) and visualized on a heatmap
357 using the ComplexHeatmap package (<https://github.com/jokergoo/ComplexHeatmap>). Volcano plots, visualized
358 via the R package EnhancedVolcano (<https://github.com/kevinblighe/EnhancedVolcano>), used the same log₂FC
359 method as mentioned, but were statistically compared using two-tailed, Wilcoxon-rank sum tests. Receiver
360 operator characteristic curves (ROC) were generated using the R package cutpointr (47) with the predicting
361 variable as relative abundance of either *Enterococcus* or *Enterobacterales* and the outcome variable as
362 *Enterococcus* or *Enterobacterales* infection, respectively. ROC curves were optimized for the Youden index and
363 visualized using ggplot2. (48) Sparse partial least squares discriminatory analysis (sPLS-DA) was constructed
364 using the R package mixOmics and required an input matrix of samples by metabolites. Models were tuned
365 using 5-fold cross-validation repeated 50 times (mixOmics::perf and mixOmics::tune.splsda). The main
366 hyperparameters that required tuning were the number of optimal components to retain in the model, number
367 of metabolites to keep in the final model, as well as distance metric, for which we used the maximum distance
368 “max.dist”. The final model was built (mixOmics::splsda) and was used to predict classes of either diversity group
369 or infection (predict). Background predictions (shaded areas on Figure 6), were constructed using the final sPLS-
370 DA model (mixOmics::background.predict). Additional model metrics for predicting bacterial infection were
371 obtained via the R package caret::confusionMatrix (49) or epiR::epi.tests. (50) Since the model for predicting
372 diversity groups included a multi-class prediction, additional model metrics were obtained from using the R
373 package mltest::ml_test. (51) The inclusion flow diagram was built using the R package
374 PRISMAstatement::flow_exclusions. (52) All data and code are available on both Github
375 (https://github.com/DFI-Bioinformatics/Microbiome_Liver_Transplant) and Zenodo
376 (<https://zenodo.org/badge/latestdoi/592530758>).

377 *Conflict of Interest:*

378 The authors have declared that no conflict of interest exists.

379 *Study approval:*

380 This study received approval by the institutional review board at the University of Chicago for human subjects
381 research (IRB20-0163). At the time of enrollment, all study procedures were explained and written informed
382 consent was obtained from the subject and/or an approved surrogate decision maker. Healthy donors were
383 identified separately from LT patients. Written informed consent was also obtained from HD prior to
384 participation.

385 **AUTHOR CONTRIBUTIONS:**

386 CJL designed research studies, obtained ethical approval, enrolled patients, developed sample collection and
387 handling protocols, analyzed data, edited figures, wrote the manuscript. NPD performed, designed, and
388 modified all data analysis, built figures, performed statistical analysis, and influenced study direction. MO
389 enrolled patients, collected samples, and contributed to study direction. RN built patient enrollment, sample
390 collection, and sample processing protocols. MK enrolled patients, collected samples, and abstracted data. JB
391 enrolled patients, collected samples, and abstracted data. EA enrolled patients, collected samples, abstracted
392 data, and maintained ethical approval. MRS contributed to study direction. MDC contributed to study direction.
393 AM contributed to study direction. HL contributed to study direction, analyzed data, and edited figures. AS
394 performed metagenomic sequencing of all samples. JLC assisted in metabolomic measurements. AMS
395 performed metabolomic measurements. EGP designed research studies, provided guidance of patient
396 population, clinical questions, sample collection protocols, metagenomic sequencing methods, metabolomic
397 profile design, and secured funding for all studies. AA influenced study design, and guided clinical associations.
398 JF influenced study design and guided clinical associations. TBB initiated the study in LT patients, identified
399 clinical end points, helped establish recruitment and sample collection. AK designed research studies,
400 established clinical end points, maintained recruitment and sample collection, and guided study findings.

401 **ACKNOWLEDGMENTS:**

402 Thank you to the Duchossois Family Institute, for establishing the metagenomic and metabolomic platforms
403 used in this study, funding the study, and guiding the mission of the research.

404 **REFERENCES:**


- 405 1. Annavajhala MK et al. Colonizing multidrug-resistant bacteria and the longitudinal evolution of the intestinal
406 microbiome after liver transplantation. *Nat Commun* 2019;10(1). doi:10.1038/s41467-019-12633-4
- 407 2. Macesic N et al. Genomic Surveillance Reveals Diversity of Multidrug-Resistant Organism Colonization and
408 Infection: A Prospective Cohort Study in Liver Transplant Recipients. *Clinical Infectious Diseases* 2018;67(6):905–
409 912.
- 410 3. Bajaj JS. Alcohol, liver disease and the gut microbiota. *Nat Rev Gastroenterol Hepatol* 2019;16(4):235–246.
- 411 4. Duong N, Bajaj JS. The impact of the gut microbiome on liver transplantation. *Curr Opin Organ Transplant*
412 2021;26(6):587–594.
- 413 5. Smith PM et al. The microbial metabolites, short-chain fatty acids, regulate colonic T reg cell homeostasis.
414 *Science (1979)* 2013;341(6145):569–573.
- 415 6. Arpaia N et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation.
416 *Nature* 2013;504(7480):451–455.
- 417 7. Campbell C et al. Bacterial metabolism of bile acids promotes generation of peripheral regulatory T cells.
418 *Nature* 2020;581(7809):475–479.
- 419 8. Li W et al. A bacterial bile acid metabolite modulates Treg activity through the nuclear hormone receptor
420 NR4A1. *Cell Host Microbe* 2021;29(9):1366-1377.e9.
- 421 9. Gutiérrez-Vázquez C, Quintana FJ. Regulation of the Immune Response by the Aryl Hydrocarbon Receptor.
422 *Immunity* 2018;48(1):19–33.
- 423 10. Furusawa Y et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T
424 cells. *Nature* 2013;504(7480):446–450.
- 425 11. Moreno R, Berenguer M. Post-liver transplantation medical complications. *Ann Hepatol* 2006;5(2):77–85.
- 426 12. Chiang D et al. Association between gut colonization of vancomycin-resistant enterococci and liver
427 transplant outcomes. *Transplant Infectious Disease* 2022;24(3). doi:10.1111/tid.13821
- 428 13. Pereira MR et al. Risk factors and outcomes of carbapenem-resistant *Klebsiella pneumoniae* infections in
429 liver transplant recipients. *Liver Transplantation* 2015;21(12):1511–1519.

- 430 14. Dubin K, Pamer EG. Enterococci and Their Interactions with the Intestinal Microbiome. *Microbiol Spectr*
431 2017;5(6). doi:10.1128/microbiolspec.bad-0014-2016
- 432 15. Sorbara MT, Pamer EG. Interbacterial mechanisms of colonization resistance and the strategies pathogens
433 use to overcome them. *Mucosal Immunol* 2019;12(1). doi:10.1038/s41385-018-0053-0
- 434 16. Taur Y et al. Intestinal domination and the risk of bacteremia in patients undergoing allogeneic
435 hematopoietic stem cell transplantation. *Clinical Infectious Diseases* 2012;55(7):905–914.
- 436 17. Stoma I et al. Compositional Flux Within the Intestinal Microbiota and Risk for Bloodstream Infection With
437 Gram-negative Bacteria. *Clinical Infectious Diseases* 2021;73(11):E4627–E4635.
- 438 18. Donskey C et al. *Effect of Antibiotic Therapy on the Density of Vancomycin-Resistant Enterococci in the Stool*
439 *of Colonized Patients*. 2000:
- 440 19. Donskey CJ. *The Role of the Intestinal Tract as a Reservoir and Source for Transmission of Nosocomial*
441 *Pathogens*. 2004:
- 442 20. Buffie CG et al. Precision microbiome reconstitution restores bile acid mediated resistance to *Clostridium*
443 *difficile*. *Nature* 2015;517(7533):205–208.
- 444 21. Kim SG et al. Microbiota-derived lantibiotic restores resistance against vancomycin-resistant *Enterococcus*.
445 *Nature* 2019;572(7771):665–669.
- 446 22. Sorbara MT et al. Inhibiting antibiotic-resistant Enterobacteriaceae by microbiota-mediated intracellular
447 acidification. *Journal of Experimental Medicine* 2019;216(1):84–98.
- 448 23. Jacobson A et al. A Gut Commensal-Produced Metabolite Mediates Colonization Resistance to *Salmonella*
449 *Infection*. *Cell Host Microbe* 2018;24(2):296-307.e7.
- 450 24. Djukovic A et al. *Lactobacillus* supports Clostridiales to restrict gut colonization by multidrug-resistant
451 Enterobacteriaceae. *Nat Commun* 2022;13(1). doi:10.1038/s41467-022-33313-w
- 452 25. Kriss M, Verna EC, Rosen HR, Lozupone CA. Functional Microbiomics in Liver Transplantation: Identifying
453 Novel Targets for Improving Allograft Outcomes. *Transplantation* 2019;103(4):668–678.
- 454 26. Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: Pathophysiological basis for therapy.
455 *J Hepatol* 2020;72(3):558–577.
- 456 27. Qin N et al. Alterations of the human gut microbiome in liver cirrhosis.. *Nature* 2014;513(7516):59–64.

- 457 28. Blanco-Miguez A et al. Extending and improving metagenomic taxonomic profiling with uncharacterized
458 species with MetaPhlan 4 [Internet] doi:10.1101/2022.08.22.504593
- 459 29. Funabashi M et al. A metabolic pathway for bile acid dehydroxylation by the gut microbiome. *Nature*
460 2020;582(7813):566–570.
- 461 30. Paik D et al. Human gut bacteria produce TH17-modulating bile acid metabolites. *Nature*
462 2022;603(7903):907–912.
- 463 31. Putnam EE, Goodman AL. B vitamin acquisition by gut commensal bacteria. *PLoS Pathog* 2020;16(1).
464 doi:10.1371/journal.ppat.1008208
- 465 32. Meijers BKI et al. p-Cresol and cardiovascular risk in mild-to-moderate kidney disease. *Clinical Journal of the*
466 *American Society of Nephrology* 2010;5(7):1182–1189.
- 467 33. Bargossi E et al. The capability of tyramine production and correlation between phenotypic and genetic
468 characteristics of *Enterococcus faecium* and *Enterococcus faecalis* strains. *Front Microbiol* 2015;6(DEC).
469 doi:10.3389/fmicb.2015.01371
- 470 34. le Cao K-A, Rohart F, Gonzalez I, Dejean S. mixOmics: Omics Data and Integration Project
471 [Internet]2016;<https://CRAN.R-project.org/package=mixOmics>. cited
- 472 35. BOHNHOFF M, MILLER CP. Enhanced susceptibility to *Salmonella* infection in streptomycin-treated mice.. *J*
473 *Infect Dis* 1962;111:117–27.
- 474 36. FRETHER R. The fatal enteric cholera infection in the guinea pig, achieved by inhibition of normal enteric flora..
475 *J Infect Dis* 1955;97(1):57–65.
- 476 37. Kinnebrew MA et al. Interleukin 23 Production by Intestinal CD103 +CD11b + Dendritic Cells in Response to
477 Bacterial Flagellin Enhances Mucosal Innate Immune Defense. *Immunity* 2012;36(2):276–287.
- 478 38. Wang B, Zhou Z, Li L. Gut Microbiota Regulation of AHR Signaling in Liver Disease. *Biomolecules* 2022;12(9).
479 doi:10.3390/biom12091244
- 480 39. Tacconelli E et al. Antibiotic usage and risk of colonization and infection with antibiotic-resistant bacteria: A
481 hospital population-based study. *Antimicrob Agents Chemother* 2009;53(10):4264–4269.
- 482 40. Buffie CG et al. Profound alterations of intestinal microbiota following a single dose of clindamycin results in
483 sustained susceptibility to *Clostridium difficile*-induced colitis. *Infect Immun* 2012;80(1):62–73.

- 484 41. Yan J et al. A compilation of fecal microbiome shotgun metagenomics from hematopoietic cell
485 transplantation patients. *Sci Data* 2022;9(1). doi:10.1038/s41597-022-01302-9
- 486 42. Termeie O et al. Alarming Trends: Mortality from Alcoholic Cirrhosis in the United States. *American Journal*
487 *of Medicine* 2022;135(10):1263–1266.
- 488 43. Bolger AM, Lohse M, Usadel B. Trimmomatic: A flexible trimmer for Illumina sequence data. *Bioinformatics*
489 2014;30(15):2114–2120.
- 490 44. Haak BW et al. Impact of gut colonization with butyrate-producing microbiota on respiratory viral infection
491 following allo-HCT. *Blood* 2018;131(26):2978–2986.
- 492 45. Sjoberg DD, Whiting K, Curry M, Lavery JA, Larmarange J. Reproducible Summary Tables with the gtsummary
493 Package. *R J* 2021;13(1):570.
- 494 46. Kassambra A. rstatix: Pipe-Friendly Framework for Basic Statistical Tests_. R package version 0.7.1
495 [Internet][published online ahead of print: 2022];<https://cran.r-project.org/package=rstatix>. cited
- 496 47. Thiele C, Hirschfeld G. Cutpointr: Improved estimation and validation of optimal cutpoints in r. *J Stat Softw*
497 2021;98. doi:10.18637/jss.v098.i11
- 498 48. Wickham H. *ggplot2*. New York, NY: Springer New York; 2009:
- 499 49. Kuhn M. caret: classification and regression training. *Astrophysics Source Code Library* 2015;ascl:1505.003.
- 500 50. Stevenson M et al. epiR: Tools for the Analysis of Epidemiological Data_. R package version 2.0.53
501 [Internet]2022;<https://CRAN.R-project.org/package=epiR>. cited
- 502 51. Dudnik G. mltest: Classification Evaluation Metrics_. R package version 1.0.1 [Internet]2018;[https://cran.r-](https://cran.r-project.org/package=mltest)
503 [project.org/package=mltest](https://cran.r-project.org/package=mltest). cited
- 504 52. Wasey J. PRISMAstatement: Plot Flow Charts According to the “PRISMA” Statement_. R package version
505 1.1.1 [Internet]2019;<https://CRAN.R-project.org/package=PRISMAstatement>. cited
- 506

507 Figure 1



508

509 **Microbiome compositions of LT recipients vary widely.** (A) Fecal microbiome composition plots of liver
 510 transplant (LT) patients and healthy donors (HD) vertically organized by relative abundance and color coded by
 511 taxa. Individual samples were ordered horizontally by Shannon diversity. (B) taxUMAP1 plot of taxonomic
 512 composition, HD are denoted as triangles. Samples are color coded by the most abundant taxon and size
 513 determined by the relative abundance of that taxon. (C-E) Comparison of Alpha diversity between LT diversity
 514 groups and between high diversity and HD using (C) Inverse Simpson, (D) Shannon, and (E) Richness. (F-J)
 515 Comparison of relative abundance of select taxa between LT diversity groups and HD. (F) *Lachnospiraceae*; (G)
 516 *Enterococcus*; (H) *Enterobacteriales*; (I) *Bacteroidetes*; (J) *Oscillospiraceae*. Significance tested by Kruskal-Wallis
 517 test *p < 0.05 **p < 0.01 ***p < 0.001 ****p < 0.0001

518 Figure 2




519

520 **Qualitatively measured microbiome derived fecal metabolites vary widely among LT recipients.** Individual
 521 metabolite abundances represented on a colorimetric heat map by log₂ fold change from the mean between
 522 samples. Red indicating increased abundance; blue indicating reduced abundance. Significance was measured
 523 between LT groups using the Kurskal-Wallis test and denoted on a colorimetric scale where green represents
 524 lower p-values, adjusted for multiple comparisons. HD were included for visual comparison. Add. Compounds
 525 include kynurenine pathway and phenolic aromatics. Abbreviations: 1°-Primary; 2°-Secondary; Add.-Additional;

526 3-Oxo-D-Or-3-Oxocheno.-1-Oxo-Deoxycholic or 3-Oxochenodeoxycholic acid, which could not be completely
527 discriminated chromatographically and are included together.

528

529 Figure 3



530

531 **Quantitatively measured microbiome derived fecal metabolites vary widely among LT recipients. Absolute**
 532 abundances of acetate, propionate, butyrate, cholic acid, glycocholic acid, taurocholic acid, deoxycholic acid,
 533 lithocholic acid, and alloisolithocholic acid compared between LT diversity groups and between high diversity LT
 534 and HD. *p < 0.05 **p < 0.01 ***p < 0.001 ****p < 0.0001


535 Table 1

	No Infection	Infection	p		No Infection	Infection	p
Demographics # (%)				Disease Severity # (%)			
Male	44 (53.7)	16 (64.0)	0.88	MELD-Na med [IQR]	28 [19,33]	30 [19,33]	0.5
Age med [IQR]	55 [41,63]	59 [46,68]	0.35	Dialysis	22 (27.2)	9 (34.6)	1
Race			.88	Pressers	6 (7.4)	5 (19.2)	1
White	54 (65.4)	17 (65.4)		Ventilation	5 (6.2)	2 (7.7)	1
Black/African-American	9 (1.1)	2 (7.7)		Immunosuppression			
More than one Race	8 (9.9)	2 (7.7)		Basiliximab	54 (66)	18 (72)	1
Asian/Mideast Indian	6 (7.4)	2 (7.7)		Tacrolimus	82(100)	25(100)	1
AI or AN	1 (1.2)	0 (0.0)		Mycophenolate	72(89)	24(96)	1
Declined	4 (4.9)	1 (3.8)		Corticosteroid	82(100)	25(100)	1
Unknown	0 (0.0)	2 (7.7)		Antibiotics			
Indication				Pip/Tazo	70 (85)	23 (92)	1
Alcoholic Cirrhosis	40 (48.8)	8 (32)	0.88	Cefepime	26 (32)	11 (44)	1
Malignancy	17 (21.0)	6 (23.1)	1	Ceftriaxone	16 (20)	7 (28)	1
NAFLD/NASH	10 (12.3)	6 (23.1)	0.88	Meropenem	4 (4.9)	1 (4.0)	1
Alcoholic Hepatitis	6 (7.4)	2 (7.7)	1	Ciprofloxacin	15 (18)	4 (16)	1
PSC	6 (7.4)	0 (0.0)	0.88	Vancomycin IV	42 (51)	17 (68)	1
Autoimmune	5 (6.2)	0 (0.0)	0.88	Vancomycin PO	1 (1.2)	1 (4.0)	1
Cryptogenic	4 (4.9)	1 (3.8)	1	Metronidazole	34 (42)	12 (48)	1
Acute Viral Hepatitis	4 (4.9)	0 (0.0)	0.88	Rifaximin	37 (45)	12 (48)	1
Chronic Hepatitis C	4 (4.9)	0 (0.0)	0.88	Gentamicin	1 (1.2)	1 (4.0)	1
Wilson's Disease	2 (2.5)	1 (3.8)	1	Tobramycin	4 (4.9)	3 (12)	1
Chronic Hepatitis B	0 (0.0)	1 (3.8)	0.88	Daptomycin	1 (1.2)	3 (12)	0.83
Hemochromatosis	0 (0.0)	1 (3.8)	0.88	Total	82	25	
DILI	1 (1.2)	0 (0.0)	1				
Other	8 (9.8)	5 (20.0)	0.88				

536

537 **Demographic and clinical characteristics of LT patients with and without infection.** Variables represented as
 538 number and percent or median and interquartile range. Other indication for transplant includes: congestive
 539 hepatopathy, primary biliary cirrhosis, and unidentified. Immunosuppressive medications were included if given
 540 within the 30 day post operative period. Antibiotics were included if given in the first 7 pre-operative days or the
 541 day of LT. p-values obtained by Chi-squared goodness of fit and adjusted for multiple comparisons.
 542 Abbreviations: AI-American Indian; AN-Alaska Native; NAFLD-Non-Alcoholic Fatty Liver Disease; NASH-Non-
 543 Alcoholic Steatohepatitis; PSC-Primary Sclerosing Cholangitis; DILI-Drug Induced Liver Injury; MELD-Na – Model
 544 for End State Liver Disease Na; Pip/Tazo – Piperacillin/Tazobactam; IV-Intravenous; PO – *per orem*.

545 Figure 4



546

547 **Enterococcus and Enterobacteriales expansion in the gut microbiome predicts postoperative infection. (A)**

548 Fecal microbiome composition plots color coded by taxon. Plots are categorized by presence of bacterial

549 infection and ordered by descending relative abundance of *Enterococcus*. Colored tiles indicate an infection

550 caused by the denoted organism associated with that stool sample. For taxonomic color palate refer to Figure 1.

551 (B) Receiver operator curve using Enterococcus abundance to predict *Enterococcus* infection. Cut point

552 determined by Youden Index to optimize both sensitivity and specificity. 95% Confidence intervals for Accuracy


553 (0.74-0.91), Specificity (59-94%), and Sensitivity (65-100%). (C) Fecal microbiome composition plots organized by

554 relative abundance of *Enterobacteriales*. (D) Receiver operator curve using *Enterobacteriales* abundance to

555 predict *Enterobacteriales* infection. 95% Confidence intervals Accuracy (0.82-0.96), Specificity (72-94%), and

556 Sensitivity (100-100%). Abbreviations: AUC-Area under the curve; ACC-Accuracy; Spec.-Specificity; Sens.-
557 Sensitivity.

558 Figure 5




559

560 **Microbiome derived fecal metabolites are enriched in LT recipients with and without *Enterococcus* expansion.**

561 (A) Volcano plot comparing Log₂ fold change of qualitative metabolite concentration from the mean, and Log₁₀
 562 scale p-value adjusted for multiple comparisons. Only metabolites with Log₂ fold change ≥ +/-1 and p ≤ 0.05 were
 563 labeled. (B-K) Quantitative metabolite comparison of select metabolites. (B) Acetate (C) Butyrate (D) Propionate
 564 (E) Taurocholic acid (F) Cholic acid (G) 3-Oxolithocholic acid (H) Alloisolithocholic acid (I) Deoxycholic acid (J)
 565 Isoodeoxycholic acid (K) Lithocholic acid. Significance tested by Kruskal-Wallis test.

566 Figure 6




	Predicted Low	Predicted Medium	Predicted High
Actual Low	34	2	1
Actual Medium	16	21	2
Actual High	7	3	16

	Predicted Infection	Predicted No Infection
Actual Infection	34	2
Actual No Infection	16	21

567

568 **Microbiome derived fecal metabolites identify low, medium, and high diversity samples and post operative**
 569 **infection.** (A) sPLS-DA using input matrix of sample metabolites and predicted microbial diversity group.
 570 Comparison between predicted groups was visualized on a grid with dividing lines and optimized by maximum
 571 distance between groups. Accuracy was: Low Diversity 77%, Medium Diversity 72%, and High Diversity 78%.
 572 Sensitivity ranged from 60-84%. Specificity ranged from 62-95%. (B) sPLS-DA using input matrix of sample
 573 metabolites and predicted postoperative infection. Comparison between outcomes was visualized on a grid with
 574 a dividing line and optimized by maximum distance between groups. Accuracy was 82.2% [73.9-89.1%],
 575 sensitivity was 63% [42.4-80.6], specificity was 88.9% [80-94.8%], and odds ratio was 13.6 [4.8-38.6].


576 Supplemental Figure 1



577

578 **Flow diagram of inclusion and exclusion criteria.** 28 patients were excluded because they had not yet
579 undergone a LT. 23 patients were excluded because a sample wasn't collected within -7 to 30 days post LT. 107
580 patients were included for analysis, 25 developed postoperative bacterial infection, 82 did not.

581 Supplemental Figure 2



582

583

584 **Time to first stool collection relative to day of liver transplant.** (A) Histogram of first stool collections
585 normalized to the day of transplant. The median being post operative day 4. The majority falling between day -7
586 and +7. (B) Median and IQR of day to first stool sample collected by diversity group. No significant difference
587 existed between groups, suggesting perioperative antibiotics don't explain the difference in microbiome
588 composition between groups.

589 Supplemental Table 1

	#(%)
Enterococcus	18 (45)
<i>E. faecium</i>	14 (35)
<i>E. faecalis</i>	3 (7.5)
<i>E. avium</i>	1 (2.5)
Enterobacterales	8 (20)
<i>E. coli</i>	3 (7.5)
<i>K. pneumoniae</i>	3 (7.5)
<i>P. mirabilis</i>	1 (2.5)
<i>C. freundii</i>	1 (2.5)
Other Bacteria	14 (35)
<i>S. aureus</i>	3 (7.5)
<i>P. aeruginosa</i>	2 (5)
<i>S. maltophilia</i>	1 (2.5)
<i>Bacteroides sp.</i>	1 (2.5)
<i>C. difficile</i>	1 (2.5)
<i>H. pylori</i>	1 (2.5)
Culture Negative	5 (12.5)
Site of Infection	
Abdominal	15 (50)
Skin/Surg. Site	5 (16.7)
Urinary	6 (20)
Blood Stream	2 (6.7)
Lower Airway	2 (6.7)

590

591 **Characteristics of infections.** *Enterococci* accounted for most infection, 45%. Followed by *Enterobacterales* 20%.
592 The remaining 35% of infection were caused by various other bacteria. The total number of organisms identified
593 is 40, which is greater than the number of infections (30) because of polymicrobial infections. Abbreviations:
594 Surg-Surgical.

595 Supplemental Table 2

A <i>Enterococcus</i>	≥19.9% Rel. Abd.	<19.9% Rel. Abd.	Total
Infected	15	2	17
Uninfected	29	66	95
Sensitivity	88.2%		
Specificity	69.5%		
Odds Ratio	17.1		


B <i>Enterobacterales</i>	≥2.5% Rel. Abd.	<2.5 Rel. Abd.	Total
Infected	8	0	8
Uninfected	21	83	104
Sensitivity	100%		
Specificity	79.8%		
Odds Ratio	Inf		

596 ***Enterococcus* and *Enterobacterales* expansion in the gut microbiome predicts postoperative infection.** (A)
597 44/112 (41%) of included patients had *Enterococcus* expansion ≥19.9% or higher. 88% (15/17) of infectious
598 caused by *Enterococcus* were associated with expansion of 19.9% or greater. Odds ratio for *Enterococcus*
599 infection was 17.1. (B) 29/112 (27%) of included patients had *Enterobacterales* expansion of 2.5% or higher and
600 all 100% (8/8) of infectious caused by *Enterobacterales* were associated with expansion of 2.5% or more. The
601 Odds ratio for *Enterobacterales* approached infinity, as no infections occurred in those <2.5%. In combination,
602 only 2/25 (8%) of *Enterococcus* or *Enterobacterales* infections occurred without any expansion.

603

604

605 Supplemental Figure 3




606

607 **Microbiome derived fecal metabolites identify low, medium, and high diversity samples.** Metabolite
 608 component loadings of sPLS-DA model (Figure 6A). x-axis indicates magnitude of impact on each component.
 609 Each component is color coded for which outcome it correlates, Low, Medium, and High diversity. 3-
 610 Oxodeoxycholic acid and 3-Oxochochenodeoxycholic acid could not be discredited chromatographically, so are
 611 included together.

612

613

614 Supplemental Figure 4



615

616 **Microbiome derived fecal metabolites identify postoperative infection.** Metabolite component loadings of first
 617 two components of sPSL-DA model predicting postoperative infection. (Figure 6B) The x-axis corresponds to the
 618 magnitude of impact each metabolite has on the component. Each metabolite is color coded for infection or no
 619 infection. 3-Oxodeoxycholic acid and 3-Oxochoenodeoxycholic acid could not be discredited chromatographically,
 620 so are included together.